- AU$52.98m
- AU$59.48m
- AU$122.11m
- 51
- 86
- 10
- 48
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 141.8 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.94 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0.51 | ||
| EV to EBITDA | 45.58 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -5.83% | ||
| Return on Equity | -8.34% | ||
| Operating Margin | -4.31% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | AU$m | 11.07 | 40.28 | 67.75 | 97.96 | 122.11 | 100.47 | 112.92 | 67.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
MedAdvisor Limited is an Australia-based company that is engaged in digital medication adherence solutions. The Company's segments include Australia, the United States, the United Kingdom and Asia Operations. The Company's products suite includes Medication Management Application, PlusOne Pharmacy Software and Pharma Patient Experience Platform. The Medication Management Application connects to the pharmacy from the mobile phone. The Company's subsidiaries include MedAdvisor International Pty. Ltd., Health Enterprises 2 Pty. Ltd., MedAdvisor Welam UK Ltd., MedAdvisor Welam USA Inc. and Adheris, LLC.
Directors
- Christopher Ridd NEC
- Robert Read CEO
- Simon Glover CFO
- Craig Schnuriger CTO
- Naomi Lawrie GCN
- Josh Swinnerton OTH
- Steve Watt OTH
- Rae Ann Grossman NED
- Sandra Hook NED
- Lucas Merrow NED
- Jim Xenos NED
- Last Annual
- June 30th, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 21st, 2010
- Public Since
- May 26th, 2011
- No. of Shareholders
- 2,600
- No. of Employees
- 100
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
Australian Stock Exchange - SEATS- Shares in Issue
- 551,890,637
- Address
- Level 2, 971 Burke Road, Camberwell, MELBOURNE, 3124
- Web
- https://www.medadvisor.com.au
- Phone
- +61 390953036
- Auditors
- RSM Australia Partners
Upcoming Events for MDR
Similar to MDR
4DMedical
Australian Stock Exchange - SEATS
Adherium
Australian Stock Exchange - SEATS
Ansell
Australian Stock Exchange - SEATS
Anteris Technologies
Australian Stock Exchange - SEATS
Aroa Biosurgery
Australian Stock Exchange - SEATS
FAQ
What is the Medadvisor share price?
As of Today at 21:58 UTC, shares in Medadvisor are trading at AU$0.10. This share price information is delayed by 15 minutes.
How has the Medadvisor share price performed this year?
Shares in Medadvisor last closed at AU$0.10 and the price had moved by -66.9% over the past 365 days. In terms of relative price strength the Medadvisor share price has underperformed the ASX All Ordinaries Index by -68.1% over the past year.
What are the analyst and broker recommendations for Medadvisor?
The overall consensus recommendation for Medadvisor is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Medadvisor dividend yield?
Medadvisor does not currently pay a dividend.
Does Medadvisor pay a dividend?
Medadvisor does not currently pay a dividend.
When does Medadvisor next pay dividends?
Medadvisor does not currently pay a dividend.
How do I buy Medadvisor shares?
To buy shares in Medadvisor you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Medadvisor?
As of the previous close price of AU$0.10, shares in Medadvisor had a market capitalisation of AU$52.98m.
Where are Medadvisor shares listed?
Here are the trading details for Medadvisor:
- Country of listing: Australia
- Exchange: ASX
- Ticker Symbol: MDR
What kind of share is Medadvisor?
Based on an overall assessment of its quality, value and momentum Medadvisor is currently classified as a Contrarian. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Medadvisor share price forecast for 2025?
The analyst consensus target price for shares in Medadvisor is AU$0.13. That is 35.42% above the last closing price of AU$0.10.
Analysts covering Medadvisor currently have a consensus Earnings Per Share (EPS) forecast of -AU$0.04 for the next financial year.
Find out moreWhat is the trend in the Medadvisor share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Medadvisor. Over the past six months, its share price has underperformed the ASX All Ordinaries Index by -71.37%.
As of the last closing price of AU$0.10, shares in Medadvisor were trading -67.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Medadvisor PE Ratio?
The Medadvisor PE ratio based on its reported earnings over the past 12 months is 141.8. The shares last closed at AU$0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Medadvisor?
Medadvisor's management team is headed by:
- Christopher Ridd - NEC
- Robert Read - CEO
- Simon Glover - CFO
- Craig Schnuriger - CTO
- Naomi Lawrie - GCN
- Josh Swinnerton - OTH
- Steve Watt - OTH
- Rae Ann Grossman - NED
- Sandra Hook - NED
- Lucas Merrow - NED
- Jim Xenos - NED